LTGO Stock Forecast: Latigo Biotherapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Latigo Biotherapeutics, Inc. is $50. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 1 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Latigo Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (32): Analysts have, on balance, been raising their forecasts.
Volatility (2): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
LTGO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LTGO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Sept 2026 | Guggenheim | Initiates | Buy | $50 |
| 1 Sept 2026 | Jefferies | Initiates | Buy | $50 |
| 1 Sept 2026 | Leerink Partners | Initiates | Outperform | $36 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LTGO.
This page is one stock. Monday covers all of them.
LTGO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
LTGO vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
LTGO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −144.6%
- Dividend yield
- —
Higher than 1% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Latigo Biotherapeutics, Inc. has a market value of $861.9M and an enterprise value of $91.7M.
Latigo Biotherapeutics, Inc. employs 66 people.
Data provided by Twelve Data
LTGO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at LTGO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Latigo Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about LTGO
What is the LTGO stock price forecast for 2026-2027?
The median 12-month analyst price target for Latigo Biotherapeutics, Inc. is $50, with estimates ranging from $36 to $73. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is LTGO stock a buy right now?
Of the 4 analysts covering Latigo Biotherapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Latigo Biotherapeutics, Inc. 1 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank LTGO?
As at 21 Nov 2026, Latigo Biotherapeutics, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (32 of 100).
Will LTGO stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts is $50, and Ticker Nerd's factor model ranks Latigo Biotherapeutics, Inc. 1 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the LTGO stock forecast for 2030?
No analyst covering Latigo Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LTGO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $36 to $73 over the next 12 months.
What does Latigo Biotherapeutics, Inc. do?
Latigo Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid pain medicines. Its current programs are built around NaV1.8 inhibitors, a class of compounds designed to interrupt pain signaling at its source while avoiding the addiction risks associated with opioid therapies.
About Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid pain medicines. Its current programs are built around NaV1.8 inhibitors, a class of compounds designed to interrupt pain signaling at its source while avoiding the addiction risks associated with opioid therapies. The company’s pipeline includes candidates for acute pain, chronic musculoskeletal pain, and broader acute and chronic pain applications, with oral and intravenous formulations in development. Latigo Biotherapeutics serves the pain-management market by advancing targeted therapies intended for use in settings such as postoperative care, musculoskeletal disorders, and other medically significant pain conditions. Headquartered in Thousand Oaks, California, the company operates within the biotechnology sector and is centered on creating differentiated treatments that address unmet needs in non-opioid pain control.
CEO Mr. Todd N. Smith · 66 employees · United States · https://latigobio.com